J Pharm Pharmaceut Sci

[Liora Putcha]

TheVirtual Pharmacy School Fair features workshops hosted by pharmacy schools, addressing topics that will provide attendees with knowledge and skills for navigating the pharmacy admission process and entering a Doctor of Pharmacy (Pharm.D.) program as well as workshops on Exploring Pharmacy Career Paths, Navigating Pre-Pharmacy Admissions, and Preparing for Pharmacy School. Register now!

PharmCAS is a centralized application service used to apply to multiple Doctor of Pharmacy (Pharm.D.) programs offered by schools and colleges of pharmacy. The service is designed for first-year professional Pharm.D. degree programs. PharmCAS provides access to individual pharmacy degree program admission requirements in an easy-to-find and standardized format.

The web Browser you are currently using is unsupported, and some features of this site may not work as intended. Please update to a modern browser such as Chrome, Firefox or Edge to experience all features Michigan.gov has to offer.

Welcome to the Michigan Board of Pharmacy website! Our goal is to provide up-to-date information on various topics related to the practice of pharmacy in Michigan. We hope you find this information helpful and invite you to check out our website often.

In an effort to reduce the use of paper, effective January 1, 2022, licenses issued or renewed will only be sent electronically unless a paper copy of the license is requested during the application or renewal process.

LARA is proud to be recognized as a Veteran-Friendly Employer committed to military veteran recruitment, training and retention practices. LARA is dedicated to bridging the gap between civilian and military employment and helping veterans gain and retain employment.

At the Skaggs School of Pharmacy, students from around the globe learn from award-winning faculty in a world-class medical setting. Hands-on training is dynamic, interprofessional and career-driven. From our entry-level PharmD program to flexible online degrees, our curriculum is innovative and agile, preparing students to be leaders in the emerging pharmacy careers of the future.

Interprofessional, experiential, and now with a hybrid option. From hospitals and industry settings, to clinics and pharmacies, our PharmD graduates are taking the lead optimizing medications and improving patient care.

The Tennessee Board of Pharmacy has been made aware that some licensees have received fraudulent communications from individuals claiming to be from the Board of Pharmacy, or another agency, such as the DEA. The communications, often by phone, and even by letter may threaten arrest or license suspension, demand personal information, or require the payment of fines. Please note:

T.C.A. 63-1-160 requires that on or after January 1, 2021, any prescription for a Schedule II, III, IV or V controlled substance issued by a prescriber who is authorized by law to prescribe the drug must be issued as an electronic prescription from the person issuing the prescription to a pharmacy.

A health care prescriber that is unable to comply with the electronic prescription requirement for a Schedule II, III, IV or V prior to January 1, 2021, may apply for a waiver from the requirement based on economic hardship or technological limitations that are not reasonably within the control of the health care prescriber or other exceptional circumstance demonstrated by the health care prescriber.

Please complete the electronic fillable form below and ensure your contact information and reason for requesting the waiver are filled in. Once you hit submit, you will receive an email asking you to verify your email address. Once you verify your email address you will receive a second email confirming receipt of your waiver.

Board staff is receiving calls and emails inquiring about the continued ability for pharmacists to document certain information on prescriptions for schedule II controlled substances, such as patient address.

A federal law enacted in 2019 required all federal agencies to undertake review of various informal guidance documents. As a result of this review, the federal Drug Enforcement Administration ("DEA") removed informal guidance from its website concerning changes to prescriptions for schedule II controlled substances. The National Association of Chain Drug Stores ("NACDS") issued a letter describing a private phone call with DEA officials. The letter indicated that, despite the DEA's historical guidance permitting pharmacist annotations to schedule II controlled substance prescriptions, all prescriptions for schedule II controlled substances must now arrive at the pharmacy with all elements required by 21 C.F.R. 1306.05(A) in final form.

The Arizona State Board of Pharmacy contacted the DEA for guidance on this matter. The DEA was unable to provide further definitive guidance on this topic. If the DEA issues any formal guidance or proposed rule making changes on this matter, Board staff will provide an update.

Pursuant to section 41-1093.01, Arizona Revised Statutes, an agency shall limit all occupational regulations to regulations that are demonstrated to be necessary to specifically fulfill a public health, safety or welfare concern. Pursuant to sections 41-1093.02 and 41-1093.03, Arizona Revised Statutes, you have the right to petition this agency to repeal or modify the occupational regulation or bring an action in a court of general jurisdiction to challenge the occupational regulation and to ensure compliance with section 41-1093.01, Arizona Revised Statutes.

Information on SB 190 regarding self-administered Hormonal Contraceptives dispensed without a prescription.

Information on SB 325 regarding pharmacist authorization to prescribe, dispense, and administer drugs to prevent the acquisition of Human Immunodeficiency Virus (HIV) and to perform certain tests.

Certificates are being emailed as they are processed. We no longer mail physical certificates. If you renewed online you may log back into your dashboard to reprint your certificate. Below is a link to log into your dashboard.

Current Nevada Law requires prescribers to obtain informed consent from patients regarding the potential risks of treatment using a controlled substance. On September 23, 2014, the National Transportation Safety Board safety study, Drug Use Trends in Aviation: Assessing the Risk of Pilot Impairment, issued Safety Recommendation I-14-1 that prescribers of controlled substances for pain:

The Board issues licenses to pharmacists and pharmacy interns. It also licenses pharmacies (both in Delaware and elsewhere), pharmaceutical manufacturers and distributors, medical gas dispensers and retail businesses that sell non-controlled prescription drugs for veterinary use.

Unless notified otherwise, the Board meets the third Wednesday of every month, with the exception of July and December. All meetings are open to the general public and are held in the Cannon Building, 861 Silver Lake Boulevard, in Dover. The meeting schedule is available at the State of Delaware public meeting calendar.

The Board/Commission may need to review and approve your application for licensure and will only review a complete application. A complete application includes your application and any documentation submitted through DELPROS and/or any documents submitted through the mail or email from third-parties. The Board/Commission will review your documentation at its next scheduled meeting.

Internal systems will be down for maintenance Thursday, October 20th at 6pm through Sunday, October 23rd.

The renewal portal will not be accessible during this time. Verifications and certificate printing may also be inaccessible during this time. Normal functionalities will be restored and available on Monday, October 24th.

Governor Abbott has declared a state of disaster in the following counties: Aransas, Brazoria, Calhoun, Chambers, Galveston, Harris, Jackson, Jasper, Jefferson, Matagorda, Montgomery, Newton, Nueces, Orange, Refugio, San Patricio, and Victoria.

Timothy Tucker, Pharm.D., Executive Director/Secretary, has authorized pharmacists in Texas to dispense up to a 30-day supply of medication (other than a Schedule II controlled substance) for patients affected in the counties of the disaster area under certain conditions.

TSBP will be moving to our new office location at the George H. W. Bush State Office Building soon. The TSBP website and network will be down beginning at 5pm Thursday, September 8th and the office will be closed on September 9th. TSBP will reopen on Monday, September 12th. Visit pharmacy.texas.gov/move for a detailed overview of the move timeline, along with minor anticipated impacts on some functionalities. Beginning September 13, 2022, our new address is:

Scams involving individuals impersonating state agency entities continue to be a serious issue. Scams are also becoming more sophisticated, which makes it even more important to be aware of and know how to recognize and protect yourself and your personal data from these types of scams.

Faculty in PSC receive more than $14.3 million in extramural grants and contracts each year in the areas of computational biology, structural biology, synthetic chemistry, nanomedicine, drug transportation, pharmacogenomics, and industrial pharmaceutics.

With strengths in structure-based drug design, our expertise in physical, computational, synthetic, and protein chemistry cuts across several centers of excellence in Computer Aided Drug Design, Nuclear Magnetic Resonance (NMR), and Mass Spectrometry. Innovative research in complex biological systems, proteomics, metabolomics, pharmacogenomics, and therapeutic engineering seeks to develop targeted innovative medicines and devices to improve human health. Optimization of therapeutic dosing regimens is the goal of our concentrated efforts in pharmacokinetics, pharmacometrics and drug delivery, including nanotechnology. Interdisciplinary research in collaboration with the University of Maryland School of Engineering is the primary focus of the Bio- and Nano-technology Center. Collaborative partnerships with other campuses and the US Food and Drug Administration are the focus of the Center of Excellence in Regulatory Science and Innovation and the Center for Research on Complex Generics.

3a8082e126